Analysts have followed Rapt as they view its drug, an oral pill dubbed zelnecirnon, as a possible competitor to Dupixent in conditions like eczema.
Dupixent, which was developed by Sanofi and Regeneron, is a multibillion-dollar product approved for a range of inflammatory diseases. Sales are expected to increase further still; Sanofi recently forecast the eczema market as likely to grow as fast as that of psoriasis.
As an oral medicine, Rapt’s treatment could represent a more convenient option than injectable medicines like Dupixent for moderate-to-severe cases of eczema.
